JBIO
Jade Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.83
+2.67%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- +82.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -11.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- -83.8%
- EBIT
- -52.2%
- Net income
- -83.0%
- EPS
- +95.2%
- Free cash flow
- -33.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026